profit from every $100 of sales.
$0$100
Moleculin Biotech
$8.06-6.93% today
-96.7% in 1 year
1-year low $5.301-year high $243.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Moleculin Biotech sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$33.6 million of profit last year.
SalesProfit
Moleculin Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Moleculin Biotech | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Moleculin Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -31 | -30 | -27 | -25 | |
| -31 | -30 | -27 | -25 | |
| -29 | -30 | -26 | -34 | |
| -378.75 | -376.75 | -189.14 | -28.42 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 57 | 38 | 17 | 22 |
| Cash | 43 | 24 | 4 | 9 |
| Total debt | 0 | 1 | 0 | 0 |
| Total liabilities | 5 | 12 | 6 | 7 |
| 52 | 26 | 11 | 15 | |
| 0 | 0 | 0 | 1 | |
| -46.0% | -87.8% | -180.1% | -129.1% | |
| -55.6% | -114.2% | -232.4% | -223.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -24 | -24 | -23 | |
| 0 | 0 | 0 | – | |
| -28 | -24 | -24 | -23 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 2 | 2 |
Valuation
- –
- –
- –
- 1.9×
- –
- –
- 0.2×
- -276.7%
- -408.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -162.9%
- -148.5%
- 502.7%
- -108.1%
- -164.4%
- –
Growth
- –
- –
- +4.8%
- –
- +258.6%
Financial health
- 0.3×
- 0.02
- 1.6%
- –
- 1.41
- 1.41
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 877
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -3.54 | -2.33 | −51.7% |
| Mar 20, 2026 | 2.61 | -7.77 | +133.6% |
| Nov 13, 2025 | -3.25 | -5.00 | +35.0% |
| Aug 12, 2025 | -12.25 | -9.75 | −25.6% |
| May 13, 2025 | -17.25 | -17.75 | +2.8% |
| Mar 21, 2025 | -0.37 | -1.54 | +76.0% |
| Nov 11, 2024 | -2.85 | -2.44 | −16.8% |
| Aug 13, 2024 | -55.75 | -52.50 | −6.2% |
News
Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53Seeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
44No pass
Philip Fisher
36No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
25No pass
Terry Smith
23No pass
Questions about Moleculin Biotech
Is Moleculin Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Moleculin Biotech AI analysis
What does Moleculin Biotech do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. It is in Biotechnology.
Does Moleculin Biotech pay a dividend?
No. Moleculin Biotech does not pay a dividend at the moment.
Is Moleculin Biotech stock halal?
No. Moleculin Biotech does not pass our halal screen: its cash and confirmed interest-bearing investments are 108% of its market value, at or above the 33% limit. How we check
How has Moleculin Biotech stock done over the past year?
Down 96.7% over the past twelve months, to $8.06. It traded between $5.30 and $243.80 and is 96.7% below its high.
Who are Moleculin Biotech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Moleculin Biotech's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.